129 related articles for article (PubMed ID: 29424308)
1. Staphylokinase Enzyme: An Overview of Structure, Function and Engineered Forms.
Vakili B; Nezafat N; Negahdaripour M; Yari M; Zare B; Ghasemi Y
Curr Pharm Biotechnol; 2017; 18(13):1026-1037. PubMed ID: 29424308
[TBL] [Abstract][Full Text] [Related]
2. Refolding of a staphylokinase variant y1-Sak by reverse dilution.
He J; Wang G; Xu R; Feng J; Wang J; Su H; Song H
Appl Biochem Biotechnol; 2008 Oct; 151(1):29-41. PubMed ID: 18785020
[TBL] [Abstract][Full Text] [Related]
3. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.
Szemraj J; Stankiewicz A; Rozmyslowicz-Szermińska W; Mogielnicki A; Gromotowicz A; Buczko W; Oszajca K; Bartkowiak J; Chabielska E
Thromb Haemost; 2007 Jun; 97(6):1037-45. PubMed ID: 17549308
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities.
Chen H; Mo W; Su H; Zhang Y; Song H
BMC Mol Biol; 2007 Oct; 8():88. PubMed ID: 17919340
[TBL] [Abstract][Full Text] [Related]
5. Role of staphylokinase in the acquisition of plasmin(ogen)-dependent enzymatic activity by staphylococci.
Christner RB; Boyle MD
J Infect Dis; 1996 Jan; 173(1):104-12. PubMed ID: 8537646
[TBL] [Abstract][Full Text] [Related]
6. Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini.
He J; Di J; Xu R; Zhao B
Biotechnol Appl Biochem; 2008 May; 50(Pt 1):17-23. PubMed ID: 18039183
[TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of a novel staphylokinase variant with thrombin-inhibitory activity.
Wang M; Wang Y; Wang J; Zou M; Liu S; Xu T; Cai X; Wu C; Wang J; Xu D
Biotechnol Lett; 2009 Dec; 31(12):1923-7. PubMed ID: 19685208
[TBL] [Abstract][Full Text] [Related]
8. Cloning & expression of SAK enzyme from
Muttar A; Numan IT
J Med Life; 2022 Jun; 15(6):768-771. PubMed ID: 35928367
[TBL] [Abstract][Full Text] [Related]
9. Staphylokinase as a plasminogen activator component in recombinant fusion proteins.
Szarka SJ; Sihota EG; Habibi HR; Wong S
Appl Environ Microbiol; 1999 Feb; 65(2):506-13. PubMed ID: 9925575
[TBL] [Abstract][Full Text] [Related]
10. Thrombolytic agents.
Collen D; Lijnen HR
Thromb Haemost; 2005 Apr; 93(4):627-30. PubMed ID: 15841305
[TBL] [Abstract][Full Text] [Related]
11. Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase.
Liu J; Wang Z; He J; Wang G; Zhang R; Zhao B
Acta Biochim Biophys Sin (Shanghai); 2014 Sep; 46(9):782-91. PubMed ID: 25098624
[TBL] [Abstract][Full Text] [Related]
12. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.
Kowalski M; Brown G; Bieniasz M; Oszajca K; Chabielska E; Pietras T; Szemraj Z; Makandjou-Ola E; Bartkowiak J; Szemraj J
Acta Biochim Pol; 2009; 56(1):41-53. PubMed ID: 19018330
[TBL] [Abstract][Full Text] [Related]
13. Staphylokinase requires NH2-terminal proteolysis for plasminogen activation.
Schlott B; Gührs KH; Hartmann M; Röcker A; Collen D
J Biol Chem; 1997 Feb; 272(9):6067-72. PubMed ID: 9038231
[TBL] [Abstract][Full Text] [Related]
14. Effects of endothelial cells on activity of staphylokinase.
Ueshima S; Okada K; Matsumoto H; Takaishi T; Fukao H; Matsuo O
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):522-9. PubMed ID: 8874862
[TBL] [Abstract][Full Text] [Related]
15. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots.
Lian Q; Szarka SJ; Ng KK; Wong SL
J Biol Chem; 2003 Jul; 278(29):26677-86. PubMed ID: 12736246
[TBL] [Abstract][Full Text] [Related]
16. Staphylokinase-annexin XI chimera exhibited efficient in vitro thrombolytic activities.
Chiou JF; Woon MD; Cheng SN; Hsu CH; Cherng SC; Hsieh FK; Lin SM; Shiau CY
Biosci Biotechnol Biochem; 2007 May; 71(5):1122-9. PubMed ID: 17485856
[TBL] [Abstract][Full Text] [Related]
17. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases].
Vanderschueren S
Verh K Acad Geneeskd Belg; 2000; 62(1):69-75. PubMed ID: 10769618
[TBL] [Abstract][Full Text] [Related]
18. NMR secondary structure of the plasminogen activator protein staphylokinase.
Ohlenschläger O; Ramachandran R; Flemming J; Gührs KH; Schlott B; Brown LR
J Biomol NMR; 1997 Apr; 9(3):273-86. PubMed ID: 9204556
[TBL] [Abstract][Full Text] [Related]
19. Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations.
Icke C; Schlott B; Ohlenschläger O; Hartmann M; Gührs KH; Glusa E
Mol Pharmacol; 2002 Aug; 62(2):203-9. PubMed ID: 12130670
[TBL] [Abstract][Full Text] [Related]
20. Cloning and purification of an anti-thrombotic, chimeric Staphylokinase in Pichia pastoris.
Vandana ; Kantipudi S; Maheshwari N; Sharma S; Sahni G
Protein Expr Purif; 2019 Oct; 162():1-8. PubMed ID: 31108209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
